Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

Junjie Li,Ke Da Yu,Da Pang,Changqin Wang,Jun Jiang,Suisheng Yang,Yunjiang Liu,Peifen Fu,Yuan Shen,Guojun Zhang,Yali Cao,Qi He,Shude Cui,Xijing Wang,Guosheng Ren,Xinzheng Li,Shiyou Yu,Pengxi Liu,Xiang Qu,Jinhai Tang,Ouchen Wang,Zhimin Fan,Guoqin Jiang,Jin Zhang,Jiandong Wang,Hongwei Zhang,Shui Wang,Jianguo Zhang,Feng Jin,Nanyan Rao,Binlin Ma,Ping Qing He,Binghe Xu,Zhigang Zhuang,Jianfeng Wang,Qiang Sun,Xiaofeng Guo,Miao Mo,Zhimin Shao

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

2020

PURPOSEStandard adjuvant chemotherapy for triple-negative breast cancer (TNBC) includes a taxane and an anthracycline. Concomitant capecitabine may be beneficial, but robust data to support this ar...

Keywords:

Anthracycline
Breast cancer
Capecitabine
Pathology
Taxane
Medicine
Chemotherapy
Epirubicin
Internal medicine
Docetaxel
Oncology
Triple-negative breast cancer
Cyclophosphamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations